Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

PTC Therapeutics Inc

Healthcare US PTCT

70.64USD
1.96(2.85%)

Last update at 2026-06-04T20:00:00Z

Day Range

69.4571.73
LowHigh

52 Week Range

17.5345.68
LowHigh

Fundamentals

  • Previous Close 68.68
  • Market Cap2797.13M
  • Volume1079153
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-30.58000M
  • Revenue TTM927.56M
  • Revenue Per Share TTM12.28
  • Gross Profit TTM 2.63M
  • Diluted EPS TTM-7.69

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -587.48700M -518.34000M -402.93200M -239.92600M -128.11000M
Minority interest - - - - -
Net income -559.01700M -523.90100M -438.16000M -251.57600M -128.08100M
Selling general administrative 300.10M 285.27M 245.16M 202.54M 153.55M
Selling and marketing expenses - - - - -
Gross profit 654.12M 506.26M 361.82M 294.85M 252.06M
Reconciled depreciation 128.84M 64.13M 43.49M 32.18M 26.09M
Ebit -439.92500M -374.94300M -397.87500M -192.79800M -77.00500M
Ebitda -372.57800M -378.06700M -227.81500M -116.78800M -54.12800M
Depreciation and amortization 67.35M -3.12400M 170.06M 76.01M 22.88M
Non operating income net other -49.20700M -57.87500M 85.19M 13.72M 0.13M
Operating income -439.92500M -374.94300M -397.87500M -192.79800M -115.68500M
Other operating expenses 1138.73M 913.54M 778.64M 499.78M 361.08M
Interest expense 90.87M 86.02M 56.35M 12.49M 12.55M
Tax provision -28.47000M 5.56M 35.23M 11.65M -0.02900M
Interest income - - - 12.49M 12.55M
Net interest income -90.87100M -86.02200M -56.35200M -12.49100M -12.55400M
Extraordinary items - - - - -
Non recurring 33.38M - - - -
Other items - - - - -
Income tax expense -28.47000M 5.56M 35.23M 11.65M -0.02900M
Total revenue 698.80M 538.59M 380.77M 306.98M 264.73M
Total operating expenses 1094.05M 881.21M 759.70M 487.64M 348.41M
Cost of revenue 44.68M 32.33M 18.94M 12.13M 12.67M
Total other income expense net -147.56200M -143.39700M -5.05700M -47.12800M -19.21100M
Discontinued operations - - - - -
Net income from continuing ops -559.01700M -523.90100M -438.16000M -251.57600M -128.08100M
Net income applicable to common shares -559.01700M -523.90100M -438.16000M -251.57600M -128.08100M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 1903.18M 1705.62M 1938.06M 2208.28M 1623.78M
Intangible assets 379.50M 705.89M 724.84M 715.33M 710.50M
Earning assets - - - - -
Other current assets 150.29M 105.66M -126.31100M 39.47M 17.90M
Total liab 2721.74M 2052.70M 1936.62M 1726.30M 1029.45M
Total stockholder equity -818.55500M -347.08600M 1.44M 481.98M 594.33M
Deferred long term liab - 102.83M 137.11M 136.74M 130.86M
Other current liab 580.25M 365.25M 60.75M 245.78M 197.29M
Common stock 0.07M 0.07M 0.07M 0.07M 0.06M
Capital stock 0.07M 0.07M 0.07M 0.07M 0.06M
Retained earnings -3283.57800M -2656.97400M -2097.95700M -1628.87700M -1190.49900M
Other liab - 269.48M 1051.70M 1037.27M 490.72M
Good will 82.34M 82.34M 82.34M 82.34M 82.34M
Other assets - 33.38M 46.50M 60.62M 16.41M
Cash 594.00M 410.70M 773.38M 208.81M 686.56M
Cash and equivalents - - - - -
Total current liabilities 603.10M 406.24M 509.35M 277.33M 235.86M
Current deferred revenue 0.80M 1.35M 265.75M 4.15M 8.24M
Net debt -178.97500M 292.92M -341.94200M 211.63M -372.70400M
Short term debt 16.00M 12.37M 159.81M 8.74M 20.00M
Short long term debt 194.31M - 149.54M - 20.00M
Short long term debt total 415.03M 703.63M 431.43M 420.44M 313.86M
Other stockholder equity 2466.23M 2305.02M 2123.61M 2171.75M 1795.35M
Property plant equipment - 72.59M 130.01M 33.83M 21.55M
Total current assets 1218.63M 693.78M 773.38M 1231.74M 779.28M
Long term investments - - - - -
Net tangible assets - -1135.31800M -805.74400M -315.68700M -198.51100M
Short term investments 282.74M 130.87M 583.66M 894.84M 398.54M
Net receivables 161.02M 155.61M 110.45M 69.93M 55.54M
Long term debt 1904.00M 571.72M 281.89M 309.14M 293.86M
Inventory 30.58M 21.81M 15.86M 18.70M 19.29M
Accounts payable 6.04M 27.27M 23.03M 18.66M 10.32M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -1.28500M 4.80M -24.28200M -60.95700M -10.58400M
Additional paid in capital - - - - -
Common stock total equity - 0.07M 0.07M 0.07M 0.06M
Preferred stock total equity - - - - -
Retained earnings total equity - -2656.97400M -2097.95700M -1628.87700M -1190.49900M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 19.96M 48.58M 227.49M 60.62M 30.11M
Deferred long term asset charges - - - - -
Non current assets total 684.55M 1011.83M 1164.68M 976.53M 844.50M
Capital lease obligations 130.81M 131.91M 103.94M 111.29M -
Long term debt total - 571.72M 281.89M 309.14M 293.86M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 442.64M 304.51M -505.57100M -341.79800M 21.81M
Change to liabilities 22.98M 41.65M 66.87M 40.50M 45.81M
Total cashflows from investing activities 290.18M 219.18M -561.54800M -387.23700M -42.61300M
Net borrowings 138.55M -2.22400M -28.93000M 267.60M 267.60M
Total cash from financing activities 167.95M 20.88M 668.72M 613.21M 131.57M
Change to operating activities -68.69200M -22.24600M -17.21300M -13.09000M -0.77000M
Net income -559.01700M -523.90100M -438.16000M -251.57600M -128.08100M
Change in cash 98.71M -19.09400M -79.21600M 126.03M 57.71M
Begin period cash flow 197.22M 216.31M 295.53M 169.50M 111.79M
End period cash flow 295.93M 197.22M 216.31M 295.53M 169.50M
Total cash from operating activities -356.65400M -251.33200M -194.07100M -98.63900M -27.64100M
Issuance of capital stock 50.00M 0.00000M 28.09M 323.76M 117.92M
Depreciation 128.84M 64.13M 84.87M 32.18M 26.09M
Other cashflows from investing activities -120.44400M -57.11800M -38.13400M -31.68200M -57.32500M
Dividends paid - - - - -
Change to inventory -6.66800M 1.80M 1.84M -3.45600M -5.82300M
Change to account receivables -48.46800M -44.99100M -10.48300M 11.53M -29.58900M
Sale purchase of stock 71.08M 23.10M 103.57M 345.61M 131.57M
Other cashflows from financing activities 269.23M 23.10M 686.78M 301.12M 13.65M
Change to netincome 113.77M 230.38M 65.11M 97.85M 60.05M
Capital expenditures 152.46M 85.33M 55.98M 45.44M 15.53M
Change receivables -48.46800M -44.99100M -10.48300M 11.53M -29.58900M
Cash flows other operating -11.70600M 54.74M 75.83M -24.43700M 3.81M
Exchange rate changes - - - -1.30300M -3.61100M
Cash and cash equivalents changes 101.48M -11.27300M -86.90400M 126.03M 57.71M
Change in working capital -85.33500M -23.78800M 36.91M 20.43M 14.21M
Stock based compensation 110.33M 103.51M 70.33M 42.13M 33.25M
Other non cash items 82.81M 128.33M 46.11M 49.37M 27.38M
Free cash flow -509.11400M -336.66300M -250.04800M -144.07800M -43.17100M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PTCT
PTC Therapeutics Inc		 1.96 2.85% 70.64 - - 2.16 1743.27 3.60 -10.2209
NVO
Novo Nordisk A/S		 1.75 4.17% 43.75 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.22% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 13.40 3.13% 441.74 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 9.78 1.58% 628.73 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

PTC Therapeutics Inc

100 Corporate Court, South Plainfield, NJ, United States, 07080

Key Executives

Name Title Year Born
Dr. Stuart W. Peltz Ph.D. Co-Founder, CEO & Exec. Director 1960
Dr. Allan Steven Jacobson Ph.D. Co-Founder, Chairman of Scientific Advisory Board & Independent Director 1946
Ms. Emily Luisa Hill Chief Financial Officer 1980
Dr. Neil Almstead Ph.D. Chief Technical Operations Officer 1967
Mr. Mark Elliott Boulding Exec. VP & Chief Legal Officer 1961
Mr. Eric Pauwels Chief Bus. Officer 1961
Ms. Dawn A. Svoronos Advisor 1953
Dr. Matthew B. Klein F.A.C.S., FACS, M.D., M.S., MS Chief Operating Officer 1972
Ms. Christine Utter Sr. VP, Chief Accounting Officer & Head of People Services 1978
Ms. Ellen Welch Ph.D. Chief Scientific Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.